← Back
NeuroTrials.ai
Neurology Clinical Trial Database

NMOSD mAb Meta-analysis

Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis

Year of Publication: 2026

Authors: Zammar K, Safan A, Abushalbak DJ, ..., Hamid S

Journal: Journal of Neuroimmunology

Citation: Zammar K, et al. Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis. J Neuroimmunol. 2026;417:578945.

Link: https://doi.org/10.1016/j.jneuroim.2026.578945


Clinical Question

Do monoclonal antibodies provide equivalent efficacy in AQP4-IgG seropositive versus seronegative NMOSD patients?

Bottom Line

Monoclonal antibodies are significantly more effective at preventing relapses in AQP4-IgG seropositive than seronegative NMOSD patients (34% lower relapse risk overall; 59% RRR in RCT subgroup). Safety profiles are comparable, supporting continued use in seronegative patients, but serostatus should inform treatment selection and expectations.

Major Points

  • Seropositive NMOSD patients had 34% lower relapse risk than seronegative patients on monoclonal antibodies (RR 0.66; 95% CI 0.49-0.89; p=0.007; I²=0%; 9 studies)
  • RCT-only subgroup analysis demonstrated 59% relative risk reduction favoring seropositive (RR 0.41; 95% CI 0.25-0.69; p=0.0008; I²=0%; 4 RCTs)
  • No significant difference in continuous ARR (SMD 0.23; 95% CI -0.66 to 1.13; p=0.61; I²=94%)
  • No significant difference in disability progression by EDSS (SMD 1.07; 95% CI -1.04 to 3.17; p=0.32; I²=96%)
  • Infectious adverse event rates comparable between groups (RR 1.13; 95% CI 0.70-1.84; p=0.61; I²=0%)
  • GRADE certainty: high for relapse events (RCTs only), moderate for relapse events (all studies), very low for continuous ARR and EDSS, low for infectious AEs
  • Serostatus should inform treatment selection and patient counseling regarding expected efficacy

Design

Study Type: Systematic review and meta-analysis

Randomization:

Blinding: Not applicable (meta-analysis)

Allocation: Not applicable

Enrollment Period: Database inception through January 2025

Follow-up Duration: Varied across included studies: 12 months to median >8 years

Centers: 0

Countries: Germany, Austria, Australia, India, Iran, Sweden, Egypt, Argentina, Turkey, China, Multinational

Sample Size: 1284

Analyzed: 1284

Analysis: Random-effects meta-analysis using DerSimonian-Laird method. Risk ratios via Mantel-Haenszel for dichotomous outcomes; standardized mean differences via inverse variance for continuous outcomes. Heterogeneity assessed via Cochran Q and I² statistic.

Registration: PROSPERO CRD1049290


Inclusion Criteria

  • Adult patients diagnosed with NMOSD per 2006 Wingerchuk criteria or 2015 IPND criteria
  • Both AQP4-IgG seropositive and seronegative patients
  • Treatment with monoclonal antibodies (rituximab, eculizumab, satralizumab, inebilizumab, tocilizumab, or ravulizumab)
  • RCTs or observational cohort studies (prospective or retrospective)
  • Comparative efficacy data between seropositive and seronegative groups

Exclusion Criteria

  • Case reports
  • Case series with fewer than 5 patients per serostatus group
  • Conference abstracts without full text
  • Editorials and letters
  • Review articles

Baseline Characteristics

Total Patients: 1284

AQP4-IgG Seropositive: 1010

AQP4-IgG Seronegative: 274

Number of Studies: 13

RCTs: 4

Observational Studies: 9

Included RCTs:

  • 0: SAkuraSky (Yamamura 2019)
  • 1: SAkuraStar (Traboulsee 2020)
  • 2: N-MOmentum (Marignier 2022)
  • 3: TANGO (Zhang 2020)

Arms

FieldAQP4-IgG SeropositiveControl
N1010274
InterventionMonoclonal antibody therapy (rituximab, eculizumab, satralizumab, inebilizumab, tocilizumab, or ravulizumab)Same monoclonal antibody therapies as seropositive group
DurationVariable (12 months to >8 years across studies)Variable (12 months to >8 years across studies)

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Relapse risk (dichotomous event) on monoclonal antibody therapy, comparing AQP4-IgG seropositive vs seronegative NMOSD patientsPrimarySeronegative: higher relapse risk (reference)Seropositive: 34% lower relapse risk0.660.007
Secondary0.61
Secondary0.32
Secondary0.0008
Safety0.61
RR 1.13 (95% CI 0.70-1.84); p=0.61; no significant difference between seropositive and seronegative groupsAdverse

Subgroup Analysis

Pre-planned RCT-only subgroup (Yamamura 2019, Traboulsee 2020, Marignier 2022, Zhang 2020) showed even more pronounced effect: RR 0.41 (95% CI 0.25-0.69; p=0.0008), representing 59% relative risk reduction in seropositive patients.


Criticisms

  • Substantial heterogeneity for continuous ARR (I²=94%) and EDSS (I²=96%) limits interpretation
  • Seronegative subgroup considerably smaller (n=274 vs 1010 seropositive), limiting power
  • Seronegative population is heterogeneous - may include undetected AQP4-IgG, MOGAD, and true double-seronegative patients
  • Only 2 studies contributed to safety analysis
  • Funnel plot asymmetry for ARR suggesting potential publication bias
  • Observational studies of variable quality included alongside RCTs
  • Different monoclonal antibodies pooled together despite different mechanisms

Based on: NMOSD mAb Meta-analysis (Journal of Neuroimmunology, 2026)

Authors: Zammar K, Safan A, Abushalbak DJ, ..., Hamid S

Citation: Zammar K, et al. Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis. J Neuroimmunol. 2026;417:578945.

Content summarized and formatted by NeuroTrials.ai.